Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS1 | P29475 | 4/20 | 0.55 |
| ▸ | METAP2 | P50579 | 3/20 | 0.55 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.55 |
| ▸ | MAPT | P10636 | 5/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | F2 | P00734 | 1/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | FGFR1 | P11362 | 7/20 | 0.46 |
| ▸ | FGFR2 | P21802 | 2/20 | 0.45 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27995719 | 0.86 | NOS1 (0.55) | NOS1METAP2DYRK1AMAPTALDH1A1 | |
| SCHEMBL84390 | 0.85 | MAPT (0.60) | NOS1METAP2DYRK1AMAPTALDH1A1 | |
| SCHEMBL8064332 | 0.85 | NOS1 (0.58) | NOS1METAP2DYRK1AMAPTALDH1A1 | |
| SCHEMBL18559548 | 0.82 | MAPT (0.55) | NOS1METAP2DYRK1AMAPTALDH1A1 | |
| SCHEMBL21510145 | 0.82 | MAPT (0.50) | NOS1METAP2DYRK1AMAPTALDH1A1 | |
| SCHEMBL3722916 | 0.82 | MAPT (0.54) | NOS1METAP2DYRK1AMAPTALDH1A1 | |
| SCHEMBL18737272 | 0.82 | MAPT (0.50) | NOS1METAP2DYRK1AMAPTALDH1A1 | |
| SCHEMBL14072852 | 0.79 | ALDH1A1 (0.48) | NOS1METAP2DYRK1AMAPTALDH1A1 | |
| SCHEMBL6202977 | 0.78 | NOS1 (0.50) | NOS1METAP2DYRK1AMAPTALDH1A1 | |
| SCHEMBL14534860 | 0.77 | MAPT (0.49) | NOS1METAP2DYRK1AMAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0912521-B1 | SUBSTITUTED INDAZOLE DERIVATIVES AND THEIR USE AS INHIBITORS PHOSPHODIESTERASE (PDE) TYPE IV AND THE PRODUCTION OF TUMOR NECROSIS FACTOR (TNF) | PFIZER (US) | 2005-04-06 | — | — | EP | disclosed |
| US-6716978-B2 | FOR THERAPY AND PROHYLAXIS OF INFLAMMATORY DISEASES INCLUDING JOINT INFLAMMATION, CROHN'S DISEASE, AND INFLAMMATORY BOWEL DISEASE; RESPIRATORY DISEASES SUCH AS CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) INCLUDING ASTHMA, CHRONIC BRONCHITIS | PFIZER INC | 2004-04-06 | — | — | US | disclosed |
| US-20030158189-A1 | Therapeutically active compounds based on indazole bioisostere replacement of catechol in PDE4 inhibitors | MARFAT ANTHONY (US) | 2003-08-21 | — | — | US | disclosed |
| US-6391872-B1 | SENSITIVE TO ADRENERGIC ANTAGONIST | PFIZER INC | 2002-05-21 | — | — | US | disclosed |
| US-20020058687-A1 | THERAPEUTICALLY ACTIVE COMPOUNDS BASED ON INDAZOLE BIOISOSTERE REPLACEMENT OF CATECHOL IN PDE4 INHIBITORS | MARFAT ANTHONY (US) | 2002-05-16 | — | — | US | disclosed |
| US-6211222-B1 | Substituted indazole derivatives and related compounds | PFIZER INC | 2001-04-03 | — | — | US | disclosed |
| CN-1284948-A | Indazole bioisostere replacement of catechol in therapeutically active compounds | PFIZER PROD INC (US) | 2001-02-21 | — | — | CN | disclosed |
| CN-1281441-A | Therapeutically active compounds based on indazole bioisostere replacement of catechol in PDE4 inhibitors | PFIZER PROD INC (US) | 2001-01-24 | — | — | CN | disclosed |
| US-6127398-A | Substituted indazole derivatives and related compounds | PFIZER INC (US) | 2000-10-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030158189-A1 | Therapeutically active compounds based on indazole bioisostere replacement of catechol in PDE4 inhibitors | PDE4B, PDE3B, PDE4A | NOS1 46/4885METAP2 3154/4885DYRK1A 3459/4885 |
| US-20020058687-A1 | THERAPEUTICALLY ACTIVE COMPOUNDS BASED ON INDAZOLE BIOISOSTERE REPLACEMENT OF CATECHOL IN PDE4 INHIBITORS | PDE3B, ALPI, PDE4B | NOS1 346/4885METAP2 3641/4885DYRK1A 2538/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.